Ticker LaunchIPO · IMAB
NovaBridge Biosciences
Formerly I-Mab
NovaBridge Biosciences (IMAB) priced its initial public offering on Jan 21, 2020 at $14.00 per ADS, and listed on Nasdaq Global Market. Jefferies was lead-left underwriter, joined by CICC and Huatai. Skadden, Arps, Conyers Dill & Pearman and JunHe advised the company and Davis Polk and King & Wood Mallesons advised the underwriters.
NovaBridge Biosciences is a clinical-stage biopharmaceutical company discovering and developing novel or highly differentiated biologics for diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. It was founded to take advantage of the growing biologics market in China.
- Status
- IPO
- Ticker
- IMAB
- Exchange
- Nasdaq Global Market
- Priced
- Jan 21, 2020
- IPO price
- $14.00 per ADS
- First filed
- Oct 29, 2019
- Company counsel
- Skadden, Arps, Conyers Dill & Pearman and JunHe
- Underwriters' counsel
- Davis Polk and King & Wood Mallesons
- Sector
- Biotech & pharma
- Country / state
- MD
More on this listing for subscribers
- Lock-up period and expiry date
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Oct 29, 2019
- Latest amendment Jan 14, 2020
- Final prospectus (424B4) Jan 21, 2020
- All filings on EDGAR CIK 1778016
Other Biotech & pharma IPOs in 2020
- PPD, Inc.PPD · Feb 6, 2020 · $1.62B
- Schrodinger, Inc.SDGR · Feb 6, 2020 · $202M
- Arcutis Biotherapeutics, Inc.ARQT · Jan 31, 2020 · $159.4M
- Annovis Bio, Inc.ANVS · Jan 30, 2020 · $12M
- Black Diamond Therapeutics, Inc.BDTX · Jan 30, 2020 · $201.1M
- Addex Therapeutics Ltd.ADXN · Jan 28, 2020